About Capricor Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://capricor.com/
Frequently Asked Questions
What is the 52-week range for CAPR?
The 52-week high is $40.37 and the 52-week low is $2.96.
What is the P/E ratio for CAPR?
The P/E ratio data is currently unavailable.
What is the dividend yield for CAPR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -56.60%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -181.71%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.13.
Analyst Recommendation Trends
Wall Street analyst consensus for CAPR over the last few months:
Latest CAPR News
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
The company is slated to orally present long-term trial results of deramiocel at the World Muscle Society congress in Hiroshima on October 3.
Which stocks are gapping on Wednesday?
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario
Dyne Therapeutics is reiterated as a "risky Buy" following a >30% stock decline, presenting a contrarian opportunity. Click for this DYN stock update.
Capricor Therapeutics Stock Surges: What's Going On?
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.
Why Did CAPR Stock Jump 20% After-Hours Today?
Patients switching from placebo to Deramiocel recorded 76% slower upper-limb decline and 66% slower decline in elbow-related function.
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38. These shifts reflect a wide spread in analyst opinion as investors weigh the extended FDA action date for deramiocel, the mixed advisory committee outcome, and new upper limb function data that some research views as important. Read on to see what is driving the competing narratives around Capricor...
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Compan
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21
B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
Could New Long-Term Data Support Capricor’s Duchenne Therapy?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company. The submission supports a refined proposed indication focused on upper limb function, which […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-24 | Bergmann Anthony | -400 | - | - |
| 2026-06-24 | Bergmann Anthony | -400 | $30 | $12,000 |
| 2026-06-24 | Bergmann Anthony | +400 | $3.18 | $1,272 |
| 2026-06-24 | Krasney Karen | -400 | - | - |
| 2026-06-24 | Krasney Karen | -400 | $30 | $12,000 |
| 2026-06-24 | Krasney Karen | +400 | $3.18 | $1,272 |
| 2026-06-22 | Bergmann Anthony | -500 | - | - |
| 2026-06-22 | Bergmann Anthony | -500 | $30 | $15,000 |
| 2026-06-22 | Bergmann Anthony | +500 | $3.18 | $1,590 |
| 2026-06-22 | Krasney Karen | -500 | - | - |
| 2026-06-22 | Krasney Karen | -500 | $30 | $15,000 |
| 2026-06-22 | Krasney Karen | +500 | $3.18 | $1,590 |
| 2026-05-26 | Maurer Michael T | +80,000 | - | - |
| 2026-05-18 | Bergmann Anthony | -3,000 | - | - |
| 2026-05-18 | Bergmann Anthony | +3,000 | $1.39 | $4,170 |
| 2026-05-13 | Litvack Frank | -3,937 | - | - |
| 2026-05-13 | Litvack Frank | +3,937 | $1.39 | $5,472 |
| 2026-05-01 | Bergmann Anthony | -25,000 | - | - |
| 2026-05-01 | Bergmann Anthony | -25,000 | $31.7016 | $792,540 |
| 2026-05-01 | Bergmann Anthony | +25,000 | $3.18 | $79,500 |
| 2026-05-01 | Krasney Karen | -25,000 | - | - |
| 2026-05-01 | Krasney Karen | -25,000 | $31.7019 | $792,548 |
| 2026-05-01 | Krasney Karen | +25,000 | $3.18 | $79,500 |
| 2026-04-02 | Sabar Karimah Es | -7,529 | - | - |
| 2026-04-02 | Sabar Karimah Es | -7,529 | $32 | $240,928 |
| 2026-04-02 | Sabar Karimah Es | +7,529 | $3.18 | $23,942 |
| 2026-04-01 | Sabar Karimah Es | -53,735 | - | - |
| 2026-04-01 | Sabar Karimah Es | -53,735 | $31.0268 | $1,667,225 |
| 2026-04-01 | Sabar Karimah Es | +53,735 | $4.86 | $261,152 |
| 2026-03-31 | Sabar Karimah Es | -61,265 | - | - |
| 2026-03-31 | Sabar Karimah Es | -61,265 | $30.168 | $1,848,243 |
| 2026-03-31 | Sabar Karimah Es | +61,265 | $4.86 | $297,748 |
| 2026-03-31 | Bergmann Anthony | -25,000 | - | - |
| 2026-03-31 | Bergmann Anthony | -25,000 | $30.1261 | $753,153 |
| 2026-03-31 | Bergmann Anthony | +25,000 | $3.18 | $79,500 |
| 2026-03-31 | Krasney Karen | -2,819 | - | - |
| 2026-03-31 | Krasney Karen | -21,488 | - | - |
| 2026-03-31 | Krasney Karen | -693 | - | - |
| 2026-03-31 | Krasney Karen | -25,000 | $30.1174 | $752,935 |
| 2026-03-31 | Krasney Karen | +2,819 | $3.18 | $8,964 |
| 2026-03-31 | Krasney Karen | +21,488 | $3.74 | $80,365 |
| 2026-03-31 | Krasney Karen | +693 | $1.39 | $963 |
| 2026-01-05 | Kelliher Mike | +15,500 | - | - |
| 2026-01-05 | Auwaerter Paul Gisbert | +5,420 | - | - |
| 2026-01-05 | Auwaerter Paul Gisbert | +1,360 | - | - |
| 2026-01-05 | Auwaerter Paul Gisbert | +15,500 | - | - |
| 2026-01-05 | Gotwals Philip J | +15,500 | - | - |
| 2026-01-05 | Sabar Karimah Es | +15,500 | - | - |
| 2026-01-05 | Bergmann Anthony | +2,500 | - | - |
| 2026-01-05 | Bergmann Anthony | +25,000 | - | - |
| 2026-01-05 | Bergmann Anthony | +25,000 | - | - |
| 2026-01-05 | Krasney Karen | +22,500 | - | - |
| 2026-01-05 | Krasney Karen | +22,500 | - | - |
| 2026-01-05 | Marban Linda | +7,500 | - | - |
| 2026-01-05 | Marban Linda | +100,000 | - | - |
| 2026-01-05 | Marban Linda | +50,000 | - | - |
| 2026-01-05 | Litvack Frank | +50,000 | - | - |
| 2026-01-05 | Musket David B | +15,500 | - | - |
| 2026-01-05 | DUNBAR GEORGE W JR | +15,500 | - | - |
| 2025-12-30 | Krasney Karen | -2,500 | - | - |
| 2025-12-30 | Krasney Karen | +2,500 | $1.39 | $3,475 |
| 2025-12-19 | DUNBAR GEORGE W JR | -3,000 | - | - |
| 2025-12-19 | DUNBAR GEORGE W JR | +3,000 | $1.39 | $4,170 |